HCV genotype 3: a wolf in sheep’s clothing

References

• Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–1342.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327.
   PubMed Web of Science ®Google Scholar
• Pybus OG, Cochrane A, Holmes EC, et al. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol. 2005;5(2):131–139.
   PubMedGoogle Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther. 2014;12(7):763–773.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355(23):2444–2451.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta-analysis. J Viral Hepat. 2011;18(11):745–759.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60(1):98–105.
   PubMed Web of Science ®Google Scholar
• Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 2011;18(10):e516–522.
   PubMed Web of Science ®Google Scholar
• McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174(2):204–212.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–2593.
   PubMed Web of Science ®Google Scholar
• Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73(3):387–391.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346–355.
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Stone AE, Cheng L, et al. Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. MBio. 2015;6(2):e02510.
   Web of Science ®Google Scholar
• Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol. 2015;9(3):375–385.
   PubMed Web of Science ®Google Scholar
• Clement S, Peyrou M, Sanchez-Pareja A, et al. Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology. 2011;54(1):38–49.
   PubMed Web of Science ®Google Scholar
• Clark PJ, Thompson AJ, Vock DM, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012;56(1):49–56.
   PubMed Web of Science ®Google Scholar
• Negro F. Hepatitis C virus-induced steatosis: an overview. Dig Dis. 2010;28(1):294–299.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Rossaro L, Hu KQ, et al. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology. 2010;52(3):864–874.
   PubMed Web of Science ®Google Scholar
• Pandya P, Rzouq F, Oni O. Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases. Clin Res Hepatol Gastroenterol. 2015;39(5):555–565.
   PubMed Web of Science ®Google Scholar
• Selic Kurincic T, Lesnicar G, Poljak M, et al. Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naive chronic hepatitis C patients infected with genotypes 1 and 3. Intervirology. 2014;57(1):23–30.
   PubMed Web of Science ®Google Scholar
• Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636–1642.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Desmond PV, Slavin JL, et al. Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver. J Viral Hepat. 2011;18(1):53–60.
   PubMed Web of Science ®Google Scholar
• Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38(1):75–85.
   PubMed Web of Science ®Google Scholar
• Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36(5):1266–1272.
   PubMed Web of Science ®Google Scholar
• Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes. 2010;59(2):347–357.
   PubMed Web of Science ®Google Scholar
• Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33(1):106–115.
   PubMed Web of Science ®Google Scholar
• Aziz H, Gill U, Raza A, et al. Metabolic syndrome is associated with poor treatment response to antiviral therapy in chronic hepatitis C genotype 3 patients. Eur J Gastroenterol Hepatol. 2014;26(5):538–543.
   PubMed Web of Science ®Google Scholar
• Restivo L, Zampino R, Guerrera B, et al. Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-alpha-2a plus ribavirin and RVR. J Viral Hepat. 2012;19(5):346–352.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499–1508.
   PubMed Web of Science ®Google Scholar
• Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol. 2008;48(1):28–34.
   PubMed Web of Science ®Google Scholar
• Chen L, Chen R, Wang H, et al. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409.
   PubMed Web of Science ®Google Scholar
• Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12(7):387–400.
   PubMed Web of Science ®Google Scholar
• Alsio A, Rembeck K, Askarieh G, et al. Impact of obesity on the bioavailability of peginterferon-alpha2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. PLoS One. 2012;7(5):e37521.
   PubMed Web of Science ®Google Scholar
• Lim T. Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepat Med. 2014;6:113–118.
   PubMedGoogle Scholar
• Valenti L, Pulixi E, La Spina S. IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity? Hepatol Int. 2012;6(1):356–359.
   PubMed Web of Science ®Google Scholar
• Cai T, Dufour JF, Muellhaupt B, et al. Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis. J Hepatol. 2011;55(3):529–535.
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Romano M, Stroffolini T, et al. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b. BMC Gastroenterol. 2012;12:162.
   PubMed Web of Science ®Google Scholar
• Lu L, Li C, Yuan J, et al. Full-length genome sequences of five hepatitis C virus isolates representing subtypes 3g, 3h, 3i and 3k, and a unique genotype 3 variant. J Gen Virol. 2013;94(Pt 3):543–548.
   PubMed Web of Science ®Google Scholar